• Rebecca L Robinson, Kurt Kroenke, David A Williams, Philip Mease, Yi Chen, Douglas Faries, Xiaomei Peng, Danette Hann, Madelaine Wohlreich, and Bill McCarberg.
• Eli Lilly and Company, Indianapolis, Indiana.
• Pain Med. 2013 Sep 1;14(9):1400-15.

ObjectiveTo describe 12-month treatment patterns and outcomes for patients starting a new medication for fibromyalgia in routine clinical practice.Design And Outcome MeasuresData from 1,700 patients were collected at baseline and 1, 3, 6, and 12 months. Repeated measures and Poisson regression models controlling for demographic, clinical, and baseline outcomes were used to assess changes in health outcomes (Brief Pain Inventory severity and interference, Sheehan Disability Scale, Fibromyalgia Impact Questionnaire), satisfaction, and economic factors for patients who initiated on pregabalin (214, 12.6%), duloxetine (264, 15.5%), milnacipran (134, 7.9%), or tricyclic antidepressants (66, 3.9%). Sensitivity analyses were run using propensity-matched cohorts.ResultsPatients started on 145 unique drugs for fibromyalgia, and over 75% of patients took two or more medications concurrently for fibromyalgia at each time point assessed. Overall, patients showed improvement on the four health outcomes, with few differences across medication cohorts. At baseline, patients reported annual averages of 20.3 visits for outpatient care, 27.7 missed days of work, and 32.6 days of care by an unpaid caregiver. The duloxetine and milnacipran (vs pregabalin or tricyclic antidepressant) cohorts had fewer outpatient visits during the 12-month study. Patients reported satisfaction with overall treatment and their fibromyalgia medication (46.0% and 42.8%, respectively).ConclusionsIn this real-world setting, patients with fibromyalgia reported modest improvements, high resource, and medication use, and were satisfied with the care they received. Cohort differences were difficult to discern because of the high rates of drug discontinuation and concomitant medication use over the 12-month study period.Wiley Periodicals, Inc.

19 keywords...

hide…